Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Alzheimer’s disease (AD) is the foremost cause of dementia, accounting for approximately 60% to 80% of all cases of dementia. This condition is a progressive and neurodegenerative ailment characterized by three principal features within the brain: Amyloid plaques, anomalous clumps formed from proteins, remnants of neurons, and fragments of other nerve cells. Neurofibrillary tangles (NETs), knotted bundles of fibers, containing clusters of a protein known as tau, are situated within neurons. The deterioration of connections between neurons leads to memory and learning deficits. Alzheimer’s disease exhibits distinctive brain alterations (pathology) distinct from those of other causes of dementia, such as Lewy body disease or Cerebrovascular disease. When these coexisting pathologies are identified during a person’s lifetime, it is called mixed dementia. A common initial clinical symptom includes difficulty recollecting recent conversations, names, or events, accompanied by apathy and depression. Alzheimer’s disease typically advances gradually through three stages: early, middle, and late. The progression of Alzheimer’s disease can be categorized into seven stages:
1. Stage 1: Occurring before the onset of symptoms.
2. Stage 2: Characterized by mild forgetfulness.
3. Stage 3: Marked by noticeable memory difficulties.
4. Stage 4: Involves more than just memory loss.
5. Stage 5: Results in decreased independence.
6. Stage 6: Presents severe symptoms.
7. Stage 7: Features a loss of physical control.
While there is no known cure for Alzheimer’s disease, treatments exist to manage its symptoms. These treatments encompass:
• Cholinesterase inhibitors enhance cell-to-cell communication. Commonly prescribed cholinesterase inhibitors encompass Donepezil (Aricept), Galantamine (Razadyne), and Rivastigmine (Exelon).
• Memantine, an NMDA antagonist, is prescribed for moderate to severe Alzheimer’s.
• Lecanemab (Leqembi), an FDA-approved medication as of 2023 for individuals with mild Alzheimer’s disease and cognitive impairment.
The likelihood of developing Alzheimer’s dementia rises with age, affecting 5.3% of those aged 65-74, 13.8% of those aged 75-84, and 34.6% of those aged 85 and above. While Alzheimer’s can occur in individuals younger than 65, it is much less common, and its prevalence in this age group remains uncertain.

Thelansis’s “Alzheimer’s Disease (AD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Alzheimer’s Disease (AD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Alzheimer’s Disease (AD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Alzheimer’s Disease (AD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Alzheimer’s Disease (AD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Alzheimer’s Disease (AD), Alzheimer’s Disease (AD) market outlook, Alzheimer’s Disease (AD) competitive landscape, Alzheimer’s Disease (AD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)